Figure 2 | Signal Transduction and Targeted Therapy

Figure 2

From: Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Figure 2

Internalization of T-SA1 and T-SA2 into HER2-positive cells detected by flow cytometry and immunofluorescence. (a) Flow cytometric analysis to evaluate the internalization efficiency of T-SA1 and T-SA2 in BT474, SKBR-3 and SKOV3; red: negative control group; purple: 0 h group; green: 1 h group; blue: 4 h group; pink: 6 h group; brown: 8 h group. (b) Uptake of scFv–HSA fusion antibodies in HER2-positive cells increased with time. (c) Internalization of trastuzumab, T-SA1 or T-SA2 into MCF-7, SKBR-3 and BT474 cells (scale bars, 12.5 μm). Cells were incubated with antibodies at 4 °C for 30 min. Unbinding antibodies were washed away. The experimental groups were incubated at 37 °C for 6 h.The green spots as shown were antibodies labeled with FITC. The blue spots were cell nuclei stained with 4,6-diamidino-2-phenylindole dihydrochloride. The red spots were lysosomes stained with Lyso-Tracker Red. The yellow to orange spots in the endochylema that were shown with the red arrows were the internalized antibodies co-localized with lysosomes.

Back to article page